The artificial intelligence rally led by the so-called Magnificent 7 over the past two years has been remarkable if you owned ...

Fintel reports that on January 30, 2025, Goldman Sachs upgraded their outlook for RH (NYSE:RH) from Sell to Neutral. As of January 29, 2025, the average one-year price target for RH is $467.74/share.

Goldman Sachs has downgraded Cytek Biosciences (NASDAQ:CTKB) to sell from buy, citing increased competition and end market ...

Between you-only-live-once retail traders, big corporates buying back their stock and retirement allocation demand, the bears ...

Deep-pocketed investors have adopted a bearish approach towards Goldman Sachs Gr (NYSE:GS), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Goldman Sachs Asset Management (GSAM) is a world-renowned company that has been providing investment management, portfolio design and advisory services to individual and institutional investors ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (XTRA:0QF) from Buy to Neutral. As of January 28, 2025, the average one-year price target for Moderna is ...

Tesla (NASDAQ:TSLA) will be under the Street’s microscope today with the EV giant slated to release 4Q24 results after the ...

Fintel reports that on January 27, 2025, Goldman Sachs upgraded their outlook for Twilio (WBAG:TWLO) from Neutral to Buy. There are 1,067 funds or institutions reporting positions in Twilio.

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (BIT:1MRNA) from Buy to Neutral. As of January 28, 2025, the average one-year price target for Moderna ...

Fintel reports that on January 27, 2025, Goldman Sachs upgraded their outlook for Twilio (LSE:0LHL) from Neutral to Buy. There are 1,049 funds or institutions reporting positions in Twilio.